Glycomine Overview
- Founded
- 2014

- Status
- Private
- Employees
- 6

- Latest Deal Type
- Series B
- Latest Deal Amount
- $33M

- Investors
- 11
Glycomine General Information
Description
Provider of nanomedicines designed to develop a new generation of replacement therapies for rare diseases. The company's medicines include orphan drugs that combine replacement therapies such as substrates, enzymes and proteins with intracellular delivery vehicles consisting of bio-nano materials and ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to treat efficiently their patients with serious rare monogenic disorders of metabolism and protein misfolding.
Contact Information
- MBC BioLabs
- 733 Industrial Road
- San Carlos, CA 94070
- United States
Glycomine Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series B) | 07-Aug-2019 | $33M | 000.00 | 000.00 | Completed | Generating Revenue |
3. Early Stage VC (Series A) | 16-Nov-2016 | 0000 | 000.00 | 000.00 | Completed | Startup |
2. Accelerator/Incubator | 01-Jan-2016 | $630K | $630K | Completed | Startup | |
1. Accelerator/Incubator | Completed | Startup |
Glycomine Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B-2 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B-1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 1,337,056 | $0.000100 | $3.8 | $3.8 | 1x | $3.8 | 2% |
Glycomine Comparisons
Industry
0000 000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialGlycomine Competitors (21)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
MiNA Therapeutics | Venture Capital-Backed | London, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
00000000 | Venture Capital-Backed | Boston, MA | 000 | 00.000 | 000000000 | 00.000 |
0000000 0000000000 | Formerly VC-backed | London, United Kingdom | 00 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Corporation | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
Glycomine Executive Team (4)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Peter McWilliams Ph.D | Chief Executive Officer & Board Member | ||
Matt Wilsey | Advisor | ||
Horacio Plotkin MD | Chief Medical Officer |
Glycomine Board Members (6)
Name | Representing | Role | Since |
---|---|---|---|
Christopher Starr Ph.D | Self | Chairman | 000 0000 |
Kenneth Harrison Ph.D | Novo Holdings | Board Member | 000 0000 |
Peter McWilliams Ph.D | Glycomine | Chief Executive Officer & Board Member | 000 0000 |
Timothy Mills Ph.D | Glycomine | Board Member | 000 0000 |
Glycomine Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialGlycomine Investors (11)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Asahi Kasei Pharma America | Corporation | Minority | 000 0000 | 000000 0 | |
Mission Bay Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Novo Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | |
Chiesi Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
John Griffin | Angel (individual) | Minority | 000 0000 | 000000 0 |